Next-Generation Cancer Diagnostics Market Forecast 2015-2025 : Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies

次世代がん診断技術の世界市場:先進PCR技術、CTC検査、FISH検査、マイクロアレイ、次世代シークエンシング技術

◆タイトル:Next-Generation Cancer Diagnostics Market Forecast 2015-2025 : Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies
◆商品コード:VGAIN5081913
◆調査・発行会社:visiongain
◆発行日:2015年7月
◆ページ数:176
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、次世代がん診断技術の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・次世代がん診断技術の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・次世代がん診断技術の世界市場:セグメント別市場分析
 (先進PCR技術、In Situハイブリダイゼーション法、循環性腫瘍細胞、マイクロアレイ、次世代シークエンシング)
・地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Next-generation cancer diagnostics – our new study reveals trends, R&D progress, and predicted revenues
Where is the next-generation cancer diagnostics market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2025, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 176-page report provides 87 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in the growing next-generation cancer diagnostics market.

Forecasts from 2015-2025 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including SWOT analysis), product profiles and commercial developments.
• Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Keith Cannon, Executive Vice President, Aviva Biosciences
- Nobuyoshi Katagiri, Ph.D., Director, Diagnostics Development Department, Oncolys BioPharma

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you will find revenue forecasts to 2025 for the following submarkets:
- Advanced PCR Techniques
- In Situ Hybridisation
- Circulating Tumour Cells
- Microarray
- Next-Generation Sequencing

Our investigation discusses what stimulates and restrains business. You will understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?
You will discover individual revenue forecasts for leading national markets from 2015-2025:
- US
- Japan
- EU5 (Germany, France, UK, Italy and Spain) as a group
- China
- India
- Brazil
- Russia
- Rest of the World

There will be growth in established developed markets and in developing countries. Our analyses show that China, in particular, will continue to achieve high revenue growth to 2025. Greater uptake of existing technology and products worldwide will also stimulate the industry and market.

Leading companies and the potential for market growth
Overall world revenue for next-generation cancer diagnostics will reach $1.6bn in 2015, our work calculates. We predict strong revenue growth through to 2025. Market entry of NGS and CTCs together with increasing demand from emerging markets will increase sales to 2025.

Our work identifies which organisations that hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. See visiongain’s analysis of the leading companies developing the most innovative cancer diagnostic technologies, including these:

- Roche Diagnostics
- Abbott Laboratories
- Qiagen
- Thermo Fisher Scientific
- Agilent Technologies
- Hologic
- Illumina
- Myriad Genetics

【レポートの目次】

1. Executive Summary
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Global Next-Generation Cancer Diagnostics Market Segmentation
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Key Questions Answered by This Analytical Report
1.7 Who is This Report For?
1.8 Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain

2. Introduction to Next-Generation Cancer Diagnostics
2.1 What Is Cancer?
2.2 Cancer Diagnostics: An Overview
2.2.1 Screening
2.2.2 Diagnosis
2.2.3 Staging
2.3 Cancer Diagnosis Methods
2.3.1 Physical Examination
2.3.2 Imaging Techniques
2.3.2.1 Ultrasound
2.3.2.2 Computed Tomography (CT)
2.3.2.3 Magnetic Resonance Imaging (MRI)
2.3.2.4 Positron Emission Tomography (PET)
2.3.3 Histopathological and Cytological Techniques
2.3.4 Immunohistochemistry (IHC) Analysis
2.3.5 Circulating Tumour Cell (CTC) Analysis
2.3.6 Molecular Diagnostics and IVD
2.3.6.1 Polymerase Chain Reaction (PCR)
2.3.6.2 Multiplex PCR
2.3.6.3 Real-Time PCR (RT-PCR or qPCR)
2.3.6.4 Digital PCR (dPCR)
2.3.6.5 In Situ Hybridisation (ISH)
2.3.6.6 Microarray
2.3.6.7 Next-Generation Sequencing (NGS)
2.4 Tests for Inherited and Acquired Genetic Mutations
2.5 Companion Diagnostics (CDx)
2.6 Laboratory Developed Test (LDT)
2.7 Precision Medicine
2.8 Government Regulations
2.8.1 The US Approval and Regulation System
2.8.2 The EU Approval and Regulation System
2.9 Market Definition

3. Next-Generation Cancer Diagnostics: World Market 2015-2025
3.1 The Global Next-Generation Cancer Diagnostics Market: Overview
3.2 The Global Next-Generation Cancer Diagnostics Market Forecast 2015-2025
3.3 How Will Segmental Market Shares Change to 2025?
3.4 Biomarkers and Molecular Diagnostics
3.4.1 Biomarkers and Diagnostic Tests for Breast Cancer
3.4.2 Biomarkers and Diagnostic Tests for Prostate Cancer
3.4.3 Biomarkers and Diagnostic Tests for Colorectal Cancer
3.5 Companion Diagnostics and Collaborations between Two Industries
3.6 LDTs to be Replaced by Approved Tests
3.7 Decentralisation of Diagnostic Tests
3.8 Next-Generation Cancer Diagnostics: Drivers and Restraints 2015-2025

4. Next-Generation Cancer Diagnostics Submarkets 2015-2025
4.1 Advanced PCR Techniques
4.1.1 Advanced PCR Techniques Market Forecast 2015-2025
4.1.2 Leading Products in the Real-Time PCR Market
4.1.2.1 cobas 4800 System & Oncology Tests (Roche)
4.1.2.2 QuantStudio Dx & 7500 Fast Dx (Thermo Fisher)
4.1.2.3 Rotor-Gene Q & therascreen Tests (Qiagen)
4.1.2.4 Oncotype DX (Genomic Health)
4.1.3 Leading Products in the Digital PCR Market
4.1.4 Pap Tests Being Replaced by PCR Assays
4.1.5 Advanced PCR-Based Techniques: Drivers and Restraints 2015-2025
4.2 In Situ Hybridisation (ISH)
4.2.1 ISH Cancer Diagnostics Market Forecast 2015-2025
4.2.2 Leading Products in the ISH Cancer Diagnostics Market
4.2.3 HER2 Tests for Breast Cancer
4.2.4 ISH Cancer Diagnostics: Drivers and Restraints 2015-2025
4.3 Circulating Tumour Cells (CTCs) Analysis
4.3.1 CTCs Analysis Market Forecast 2015-2025
4.3.2 Leading Product in the CTCs Analysis Market
4.3.2.1 CellSearch System (Janssen Diagnostics)
4.3.3 Epic Sciences and LabCorp to Expand in Asia Markets
4.3.4 CTCs Separation by Ultrasound
4.3.5 CTC Clusters More Likely to Cause Metastasis?
4.3.6 CTCs Analysis: Drivers and Restraints 2015-2025
4.4 Microarray
4.4.1 Microarray Cancer Diagnostics Market Forecast 2015-2025
4.4.2 Leading Products in the Microarray Market
4.4.2.1 OncoScan FFPE Assay Kit (Affymetrix)
4.4.2.2 MammaPrint (Agendia)
4.4.3 Microarray Cancer Diagnostics: Trends and Developments
4.4.3.1 Array Comparative Genomic Hybridisation (Array CGH)
4.4.4 Microarray Cancer Diagnostics: Drivers and Restraints 2015-2025
4.5 Next-Generation Sequencing (NGS)
4.5.1 NGS Cancer Diagnostics Market Forecast 2015-2025
4.5.2 Leading Products in the NGS Market
4.5.2.1 MiSeqDx (Illumina)
4.5.2.2 Ion PGM Dx System (Thermo Fisher)
4.5.2.3 GeneRead DNAseq Targeted Panels V2 (Qiagen)
4.5.3 NGS Cancer Diagnostics: Trends and Developments
4.5.3.1 Myriad Shifting from PCR to NGS Panel
4.5.3.2 Competition in the NGS Market
4.5.3.3 Bio-Rad to Commercialise NGS system for Clinical Use
4.5.3.4 Qiagen Launched NGS Bioinformatics Platform
4.5.4 NGS Cancer Diagnostics: Drivers and Restraints 2015-2025

5. Leading National Markets 2015-2025
5.1 World Next-Generation Cancer Diagnostics Market: Regional Forecast 2015-2025
5.1.1 How Will Regional Market Shares Change to 2025?
5.2 US Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.2.1 FDA Provides Guidance for Molecular Diagnostic Instruments with Combined Functions
5.2.2 Obama Launched ‘Precision Medicine Initiative’
5.2.3 FDA and CMS to Regulate LDTs
5.3 EU5 Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.3.1 Germany: Leading Market in the EU
5.3.2 France: Reduction in Healthcare Spending
5.3.3 UK: 100,000 Genomes Project
5.3.4 Spain: Recovering from Financial Crisis
5.3.5 Italy: Decreasing Reimbursement
5.4 Japanese Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.4.1 Takeda Collaborated with NCC in Genomic Screening Project
5.4.2 Qiagen Partnered Hitachi on PCR and NGS Technologies
5.4.3 Increase Cancer Rates in Fukushima after Nuclear Disaster?
5.5 Chinese Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.5.1 Illumina Entering the Chinese Market
5.5.2 Epigenomics Colorectal Cancer Test Approved in China
5.5.3 China Offered Free Screenings for Cervical and Breast Cancer
5.6 Indian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.6.1 Lack of Genetic Testing Regulation
5.6.2 Cancer Genetics Launched NGS Cancer Panel in India
5.7 Brazilian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.8 Russian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.8.1 IBM’s Collaboration with Russian Companies to Advance Clinical Decision Making

6. Leading Companies in the Next-Generation Cancer Diagnostics Market 2015
6.1 Roche Diagnostics
6.1.1 Roche Diagnostics: Product Portfolio, 2015
6.1.2 Roche Diagnostics: Diagnostics Outlook
6.1.3 Cobas HPV Test Approved in the US in 2014
6.1.4 Roche Diagnostics: Recent M&A Activity
6.1.5 Roche Coming Back to the NGS Business?
6.2 Abbott Laboratories
6.2.1 Abbott: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.2.2 Abbott: Diagnostics Outlook
6.2.3 Abbott Obtained Exclusive License for Bladder Cancer Biomarker FGFR3
6.3 Qiagen
6.3.1 Qiagen: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.3.1.1 Molecular Diagnostics Kits
6.3.1.2 Real-Time PCR: Rotor-Gene Q
6.3.1.3 Bioinformatics for NGS
6.3.2 Qiagen: Market Outlook
6.3.3 HalioDx Created from Qiagen Marseille
6.4 Thermo Fisher Scientific
6.4.1 Thermo Fisher Scientific: Business Segments
6.4.2 Thermo Fisher: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.4.2.1 QuantStudio 3D (Digital PCR)
6.4.2.2 In Situ Hybridisation
6.4.2.3 Microarray Slides
6.4.2.4 Next-Generation Sequencing
6.4.2.5 Real-Time PCR for Oncology in Pipeline?
6.4.3 Thermo Fisher: Life Sciences Outlook
6.4.4 NGS Oncomine Focus Assay for Oncology Research
6.5 Agilent Technologies
6.5.1 Agilent: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.5.1.1 NGS Enrichment Platforms
6.5.1.2 Cytogenetic Research and Microarrays
6.5.1.3 Other Products
6.5.2 Agilent: Life Sciences and Diagnostics Outlook
6.5.3 Partnerships and Collaborations for Companion Diagnostics
6.6 Hologic
6.6.1 Hologic: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.6.1.1 Aptima HPV Assay and Cervista HPV Assay
6.6.1.2 Progensa PCA3 Assay
6.6.2 Hologic: Diagnostics Sales Outlook
6.7 Illumina
6.7.1 Illumina: Technology and Product Portfolio 2015
6.7.1.1 Sequencing Technology
6.7.1.2 BeadArray Microarray
6.7.1.3 Consumables
6.7.1.4 Services
6.7.2 Illumina: Sales Outlook
6.7.3 Illumina: Recent M&A Activity
6.7.4 Joined Forces with UK Government for 100,000 Genomes Project
6.7.5 Partnered with Merck Serono to Develop NGS Cancer Diagnostics
6.7.6 Investing on Synthetic DNA Manufacturing Technology
6.8 Myriad Genetics
6.8.1 Myriad: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.8.2 Myriad: Sales Outlook
6.8.3 New Landscape in the BRCA Diagnostic Market

7. Qualitative Analysis of the Next-Generation Cancer Diagnostics Market 2015-2025
7.1 SWOT Analysis of the Next-Generation Cancer Diagnostics Market
7.2 Strengths
7.2.1 Global Cancer Rates Set to Soar
7.2.2 Increasing Awareness of Molecular Cancer Diagnostics
7.2.3 The Trend in Precision Medicine
7.3 Weaknesses
7.3.1 Industry Facing Increasing Reimbursement Pressure
7.3.2 Physicians’ Reliance on Traditional Methods
7.4 Opportunities
7.4.1 Expanding Biomarkers and Cancer Test Menus
7.4.2 Emerging Market to Provide Future Growth
7.4.3 Companion Diagnostics on the Rise
7.5 Threats
7.5.1 Decreasing Healthcare Spending
7.5.2 Gene Patenting Banned in the US?

8. Research Interviews
8.1 Keith Cannon, Executive Vice President, Aviva Biosciences
8.1.1 Aviva: From Research Laboratories to Clinical and Diagnostic Markets
8.1.2 Ability to Distinguish CTCs is the Key
8.1.3 RedSift(TM): Automated Enrichment of Nucleated Cells
8.1.4 On Drivers and Restraints in the CTC Technologies Market
8.1.5 On the Growth in Regional Markets
8.2 Nobuyoshi Katagiri, Ph.D., Director, Diagnostics Development Department, Oncolys BioPharma
8.2.1 On Future Growth of Oncolys BioPharma
8.2.2 CTCs is Changing the Market
8.2.3 On Current Restraints in the Market
8.2.4 ctDNA May Compete with Oncolys BioPharma’s TelomeScan

9. Conclusions
9.1 The World Next-Generation Cancer Diagnostics Market
9.1.1 Current Leading Next-Generation Cancer Diagnostics Segments
9.1.2 Notable Next-Generation Cancer Diagnostics Companies
9.1.3 Leading Regional Markets
9.1.4 World Next-Generation Cancer Diagnostics Market Forecast 2015-2025
9.2 The Future of the Next-Generation Cancer Diagnostics Market

10. Glossary

List of Tables
Table 1.1 Leading National Next-Generation Cancer Diagnostics Market Forecast 2015-2025 ($m, AGR%, CAGR%)
Table 3.1 The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 3.2 Selected Biomarkers For Cancer Diagnostics
Table 3.3 FDA Approved Nucleic Acid Based Tests, 2015
Table 3.4 Selected Molecular Diagnostic Tests for Breast Cancer, 2015
Table 3.5 Selected Molecular Diagnostic Tests for Prostate Cancer, 2015
Table 3.6 Selected Molecular Diagnostics Test for Colorectal Cancer, 2015
Table 3.7 Companion Diagnostic Devices Approved by FDA, 2015
Table 4.1 Advanced PCR Techniques Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.2 ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.3 CTCs Analysis Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.4 Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.5 NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 5.1 World Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2014-2025
Table 5.2 US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.3 EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.4 Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.5 Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.6 Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.7 Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.8 Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 6.1 Roche: Overview, 2015
Table 6.2 Roche Diagnostics: Key Instrument/Device Launches Planned for 2015
Table 6.3 Roche Diagnostics: Key Test Launches Planned for 2015
Table 6.4 Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.5 Abbott Laboratories: Overview, 2015
Table 6.6 Abbott: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.7 Qiagen: Overview, 2015
Table 6.8 Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.9 Thermo Fisher: Overview, 2015
Table 6.10 Thermo Fisher: Life Sciences Solutions Segment Revenue ($m), AGR (%), 2012-2014
Table 6.11 Life Technologies: Revenue ($m), AGR (%), CAGR (%), 2008-2012
Table 6.12 Agilent: Overview, 2015
Table 6.13 Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.14 Hologic: Overview, 2015
Table 6.15 Hologic: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.16 Illumina: Overview, 2015
Table 6.17 Illumina: Sequencing Product Portfolio 2015
Table 6.18 Illumina: Microarray Product Portfolio 2015
Table 6.19 Illumina: Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.20 Myriad: Overview, 2015
Table 6.21 Myriad: Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 7.1 SWOT Analysis of the Next-Generation Cancer Diagnostics Market, 2015-2025

List of Figures
Figure 1.1 New Cancer Cases and Deaths in More Developed and Less Developed Regions in 2012
Figure 1.2 Global Next-Generation Cancer Diagnostics Market Segmentation Overview 2015
Figure 3.1 Most Common Causes of Cancer Death, 2012
Figure 3.2 The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
Figure 3.3 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2014
Figure 3.4 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2019
Figure 3.5 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2025
Figure 3.6 Next-Generation Cancer Diagnostics: Market Drivers and Restraints 2015-2025
Figure 4.1 Advanced PCR Techniques Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.2 Advanced PCR-Based Techniques: Drivers and Restraints 2015-2025
Figure 4.3 ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.4 ISH Cancer Diagnostics: Drivers and Restraints 2015-2025
Figure 4.5 CTCs Analysis Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.6 CTCs Analysis: Drivers and Restraints 2015-2025
Figure 4.7 Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.8 Microarray Cancer Diagnostics: Drivers and Restraints 2015-2025
Figure 4.9 NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.10 NGS Cancer Diagnostics: Drivers and Restraints 2015-2025
Figure 5.1 New Cancer Cases and Deaths in More Developed and Less Developed Regions in 2012
Figure 5.2 World Next-Generation Cancer Diagnostics Market: Revenues ($m) by Region, 2014-2025
Figure 5.3 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2014
Figure 5.4 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2019
Figure 5.5 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2025
Figure 5.6 US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.7 EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.8 Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.9 Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.10 Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.11 Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.12 Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 6.1 Roche Diagnostics: Revenue Share (%) by Segment, 2014
Figure 6.2 Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.3 Roche Diagnostics: Growth Rate (%) by Region, 2014
Figure 6.4 Abbott: Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.5 Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.6 Life Technologies: Revenue ($m), AGR (%), 2008-2012
Figure 6.7 Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.8 Hologic: Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.9 Illumina: Revenue Share (%) by Business Segment, 2014
Figure 6.10 Illumina: Revenue Share (%) by Geographic Area, 2014
Figure 6.11 Illumina: Revenue ($m), AGR (%), 2010-2014
Figure 6.12 Myriad: Revenue ($m), AGR (%), 2010-2014
Figure 6.13 Myriad: Revenue Share by Product (%), 2013
Figure 6.14 Myriad: Revenue Share by Product (%), 2014

【レポートのキーワード】

次世代がん診断技術、癌検査、先進PCR技術、In Situハイブリダイゼーション法、循環性腫瘍細胞、マイクロアレイ、次世代シークエンシング、CTC検査、FISH検査、がん治療

★調査レポート[次世代がん診断技術の世界市場:先進PCR技術、CTC検査、FISH検査、マイクロアレイ、次世代シークエンシング技術] ( Next-Generation Cancer Diagnostics Market Forecast 2015-2025 : Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies / VGAIN5081913) 販売に関する免責事項
[次世代がん診断技術の世界市場:先進PCR技術、CTC検査、FISH検査、マイクロアレイ、次世代シークエンシング技術] ( Next-Generation Cancer Diagnostics Market Forecast 2015-2025 : Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies / VGAIN5081913) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆